177 related articles for article (PubMed ID: 11049889)
1. Thromboelastography as a perioperative measure of anticoagulation resulting from low molecular weight heparin: a comparison with anti-Xa concentrations.
Klein SM; Slaughter TF; Vail PT; Ginsberg B; El-Moalem HE; Alexander R; D'Ercole F; Greengrass RA; Perumal TT; Welsby I; Gan TJ
Anesth Analg; 2000 Nov; 91(5):1091-5. PubMed ID: 11049889
[TBL] [Abstract][Full Text] [Related]
2. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?
Henry TD; Satran D; Knox LL; Iacarella CL; Laxson DD; Antman EM
Am Heart J; 2001 Oct; 142(4):590-3. PubMed ID: 11579347
[TBL] [Abstract][Full Text] [Related]
3. Thromboelastography for the monitoring of the antithrombotic effect of low-molecular-weight heparin after major orthopedic surgery.
Tekkesin N; Tekkesin M; Kaso G
Anatol J Cardiol; 2015 Nov; 15(11):932-7. PubMed ID: 26574762
[TBL] [Abstract][Full Text] [Related]
4. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin.
Mousa SA; Linhardt R; Francis JL; Amirkhosravi A
Thromb Haemost; 2006 Dec; 96(6):816-21. PubMed ID: 17139378
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulant effect at the time of epidural catheter removal in patients receiving twice-daily or once-daily low-molecular-weight heparin and continuous epidural analgesia after orthopedic surgery.
Douketis JD; Kinnon K; Crowther MA
Thromb Haemost; 2002 Jul; 88(1):37-40. PubMed ID: 12152674
[TBL] [Abstract][Full Text] [Related]
6. The utility of thromboelastography in monitoring low molecular weight heparin therapy in the coronary care unit.
White H; Sosnowski K; Bird R; Jones M; Solano C
Blood Coagul Fibrinolysis; 2012 Jun; 23(4):304-10. PubMed ID: 22473047
[TBL] [Abstract][Full Text] [Related]
7. Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time.
Brophy DF; Martin EJ; Gehr TW; Carr ME
Am J Kidney Dis; 2004 Aug; 44(2):270-7. PubMed ID: 15264185
[TBL] [Abstract][Full Text] [Related]
8. A case series of LMWH use in pregnancy: should trough anti-Xa levels guide dosing?
Berresheim M; Wilkie J; Nerenberg KA; Ibrahim Q; Bungard TJ
Thromb Res; 2014 Dec; 134(6):1234-40. PubMed ID: 25450535
[TBL] [Abstract][Full Text] [Related]
9. Thromboelastogram-guided enoxaparin dosing does not confer protection from deep venous thrombosis: a randomized controlled pilot trial.
Louis SG; Van PY; Riha GM; Barton JS; Kunio NR; Underwood SJ; Differding JA; Rick E; Ginzburg E; Schreiber MA
J Trauma Acute Care Surg; 2014 Apr; 76(4):937-42; discussion 942-3. PubMed ID: 24662855
[TBL] [Abstract][Full Text] [Related]
10. Does prior administration of enoxaparin influence the effects of levobupivacaine on blood clotting? Assessment using the Thrombelastograph.
Leonard SA; Lydon A; Walsh M; Fleming C; Boylan J; Shorten GD
Br J Anaesth; 2001 Jun; 86(6):808-13. PubMed ID: 11573588
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of clot formation process by treatment with the low-molecular-weight heparin nadroparin in patients with carotid artery disease undergoing angioplasty and stenting. A thromboelastography study on whole blood.
Konstantinidis K; Gerasimidis T; Verdy E; Elalamy I; Samama MM; Gerotziafas GT
Thromb Haemost; 2007 Jan; 97(1):109-18. PubMed ID: 17200777
[TBL] [Abstract][Full Text] [Related]
12. Thrombelastography monitoring of resistance to enoxaparin anticoagulation in thrombophilic pregnancy patients.
Carroll RC; Craft RM; Whitaker GL; Snider CC; Kirby RK; Elder RF; Hennessey MD
Thromb Res; 2007; 120(3):367-70. PubMed ID: 17150243
[TBL] [Abstract][Full Text] [Related]
13. Anticoagulant effects of low-molecular-weight heparins in healthy cats.
Alwood AJ; Downend AB; Brooks MB; Slensky KA; Fox JA; Simpson SA; Waddell LS; Baumgardner JE; Otto CM
J Vet Intern Med; 2007; 21(3):378-87. PubMed ID: 17552440
[TBL] [Abstract][Full Text] [Related]
14. Trauma patients with lower extremity and pelvic fractures: Should anti-factor Xa trough level guide prophylactic enoxaparin dose?
Dhillon NK; Smith EJT; Gillette E; Mason R; Barmparas G; Gewertz BL; Ley EJ
Int J Surg; 2018 Mar; 51():128-132. PubMed ID: 29367044
[TBL] [Abstract][Full Text] [Related]
15. Low-Molecular-Weight Heparin Resistance and Its Viscoelastic Assessment in Critically Ill COVID-19 Patients.
Bösch J; Rugg C; Schäfer V; Lichtenberger P; Staier N; Treichl B; Rajsic S; Peer A; Schobersberger W; Fries D; Bachler M
Semin Thromb Hemost; 2022 Oct; 48(7):850-857. PubMed ID: 36174602
[TBL] [Abstract][Full Text] [Related]
16. Thromboelastometry versus free-oscillation rheometry and enoxaparin versus tinzaparin: an in-vitro study comparing two viscoelastic haemostatic tests' dose-responses to two low molecular weight heparins at the time of withdrawing epidural catheters from ten patients after major surgery.
Thomas O; Larsson A; Tynngård N; Schött U
BMC Anesthesiol; 2015 Nov; 15():170. PubMed ID: 26603039
[TBL] [Abstract][Full Text] [Related]
17. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular- weight heparin for the treatment of venous thromboembolism.
Wilson SJ; Wilbur K; Burton E; Anderson DR
Haemostasis; 2001; 31(1):42-8. PubMed ID: 11408748
[TBL] [Abstract][Full Text] [Related]
18. Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma.
Ko A; Harada MY; Barmparas G; Chung K; Mason R; Yim DA; Dhillon N; Margulies DR; Gewertz BL; Ley EJ
JAMA Surg; 2016 Nov; 151(11):1006-1013. PubMed ID: 27383732
[TBL] [Abstract][Full Text] [Related]
19. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
[TBL] [Abstract][Full Text] [Related]
20. Thromboelastography (TEG®) demonstrates that tinzaparin 4500 international units has no detectable anticoagulant activity after caesarean section.
Griffiths S; Woo C; Mansoubi V; Riccoboni A; Sabharwal A; Napier S; Columb M; Laffan M; Stocks G
Int J Obstet Anesth; 2017 Feb; 29():50-56. PubMed ID: 27887785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
